Released May 9, 2024, after the close
10-Q filed May 9, 2024, 39 days after period end · 0001299130-24-000111
Q1 2024 · 10-Q
Revenue$38.81M$38.81M −0.2% vs Q1 2023−33.5% vs Q4 2023
Net Income-$78.18M-$78.18M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.29-$0.29 N/M vs Q1 2023no prior Q4 2023 on file
Gross Profit$11,282,000+15.6%
Operating Income-$81,362,000N/M
Operating Cash Flow-$75,682,000N/M
Free Cash Flowderived-$79,561,000N/M
Margins · derived
Gross margin29.1%+4.0 pt vs Q1 2023
Operating margin-209.6%+24.9 pt vs Q1 2023
Net margin-201.4%+24.8 pt vs Q1 2023
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $38.81M | $38.90M | $33.17M | $29.00M |
| Net Income | -$78.18M | -$88.02M | -$81.50M | -$87.44M |
| EPS Diluted | -$0.29 | -$0.36 | -$0.37 | -$0.45 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pacific Biosciences of California, Inc. · CIK 1299130 · Engraved from SEC EDGAR